Menu Login / Registration Search
CZ

CLIA Beta 2 Glycoprotein IgG

The chemiluminescence assay is intended for use as an aid in the diagnosis of antiphospholipid syndrome (APS) and other autoimmune diseases using IgG antibodies to beta-2-glycoprotein in human serum or plasma.

New
Catalog Number: CL-BGG100
Size: 100 tests
Regulatory status: CE IVD
Clinical topic: Immunology & Autoimmune Diseases
Diagnostic panel: Antiphospholipid Syndrome
Producer: TestLine Clinical Diagnostics s.r.o.
CLIA Beta 2 Glycoprotein IgG

Support for the Diagnosis of Antiphospholipid Syndrome (APS) and Other Autoimmune Diseases

Cardiolipin, a phospholipid, is a major structural component of the inner mitochondrial membrane and is also present in the plasma membrane of certain prokaryotes. Because antibodies directed against cardiolipin alone commonly occur in infectious diseases, diagnostic assays therefore utilize a complex epitope composed of cardiolipin and β2-glycoprotein I.

The diagnosis of APS is based on a combination of clinical manifestations (such as a history of thrombosis, spontaneous miscarriage, thrombocytopenia, or stroke) and laboratory findings (including the presence of IgM/IgG autoantibodies against cardiolipin and β2-glycoprotein I, detection of lupus anticoagulant antibodies, and abnormalities in coagulation testing).

Technical specifications

Technical data
References
Related Products
Downloads

Technical data

Assay time40 min
Assay stability30 days on board stability / In use stability until the expiration date at storage temperature 2-8 °C
Sample matrix Serum, Plasma
Sample volume10 µL
Measuring range0–300 IU/ml
Assay/kit contentReagent Cartridge with specific reagents for the assay, magnetic beads, calibrators
Complementary productsAnchor® Tips, Stackable Cuvette, KleeYa Trigger Pack, KleeYa Wash buffer
Note

The kits are CE-IVD certified and intended for professional use.

References

  • Knight JS, Branch DW, Ortel TL. Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management. BMJ. 2023 Feb 27;380:e069717. doi: 10.1136/bmj-2021-069717. PMID: 36849186.
    See more on PubMed
  • Sammaritano LR. Antiphospholipid syndrome. Best Pract Res Clin Rheumatol. 2020 Feb;34(1):101463. doi: 10.1016/j.berh.2019.101463. Epub 2019 Dec 19. PMID: 31866276.
    See more on PubMed
  • Schreiber K, Sciascia S, de Groot PG, Devreese K, Jacobsen S, Ruiz-Irastorza G, Salmon JE, Shoenfeld Y, Shovman O, Hunt BJ. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018 Jan 11;4:17103. doi: 10.1038/nrdp.2017.103. Erratum in: Nat Rev Dis Primers. 2018 Jan 25;4:18005. doi: 10.1038/nrdp.2018.5. PMID: 29321641.
    See more on PubMed
  • Fauchais AL, Lambert M, Launay D, Michon-Pasturel U, Queyrel V, Nguyen N, Hebbar M, Hachulla E, Devulder B, Hatron PY. Antiphospholipid antibodies in primary Sjögren's syndrome: prevalence and clinical significance in a series of 74 patients. Lupus. 2004;13(4):245-8. doi: 10.1191/0961203304lu1006oa. PMID: 15176660.
    See more on PubMed
  • Ortel TL. Antiphospholipid syndrome: laboratory testing and diagnostic strategies. Am J Hematol. 2012 May;87 Suppl 1(Suppl 1):S75-81. doi: 10.1002/ajh.23196. Epub 2012 Mar 31. PMID: 22473619; PMCID: PMC4848066.
    See more on PubMed
  • Gómez-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun. 2014 Feb-Mar;48-49:20-5. doi: 10.1016/j.jaut.2014.01.006. Epub 2014 Jan 24. PMID: 24461539.
    See more on PubMed
  • Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011 Jun;7(6):330-9. doi: 10.1038/nrrheum.2011.52. Epub 2011 May 10. PMID: 21556027.
    See more on PubMed
  • Petri M. Antiphospholipid syndrome. Transl Res. 2020 Nov;225:70-81. doi: 10.1016/j.trsl.2020.04.006. Epub 2020 May 12. PMID: 32413497; PMCID: PMC7487027.
    See more on PubMed
  • Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, Amoura Z, Andrade D, Andreoli L, Artim-Esen B, Atsumi T, Avcin T, Belmont HM, Bertolaccini ML, Branch DW, Carvalheiras G, Casini A, Cervera R, Cohen H, Costedoat-Chalumeau N, Crowther M, de Jesús G, Delluc A, Desai S, Sancho M, Devreese KM, Diz- Kucukkaya R, Duarte-García A, Frances C, Garcia D, Gris JC, Jordan N, Leaf RK, Kello N, Knight JS, Laskin C, Lee AI, Legault K, Levine SR, Levy RA, Limper M, Lockshin MD, Mayer-Pickel K, Musial J, Meroni PL, Orsolini G, Ortel TL, Pengo V, Petri M, Pons-Estel G, Gomez-Puerta JA, Raimboug Q, Roubey R, Sanna G, Seshan SV, Sciascia S, Tektonidou MG, Tincani A, Wahl D, Willis R, Yelnik C, Zuily C, Guillemin F, Costenbader K, Erkan D; ACR/EULAR APS Classification Criteria Collaborators. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2023 Oct;82(10):1258-1270. doi: 10.1136/ard-2023-224609. Epub 2023 Aug 28. PMID: 37640450.
    See more on PubMed

Downloads

Safety information

Declaration of conformity

Find documents for the lot

Do you want to learn more about products? We're here for you.

Please fill in
all fields
marked *
Up